A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA Cancer J Clin, vol.61, pp.69-90, 2011.

R. L. Coleman, B. J. Monk, A. K. Sood, and T. J. Herzog, Latest research and treatment of advanced-stage epithelial ovarian cancer, Nat Rev Clin Oncol, vol.10, pp.211-224, 2013.

L. G. Di, M. Garofalo, and C. Cm, MicroRNAs in cancer, Annu Rev Pathol, vol.9, pp.287-314, 2014.

M. V. Iorio and C. M. Croce, Causes and consequences of microRNA dysregulation, Cancer J, vol.18, pp.215-222, 2012.

Y. Kinose, K. Sawada, K. Nakamura, and T. Kimura, The role of microRNAs in ovarian cancer, Biomed Res Int, p.249393, 2014.

S. Djebali, C. A. Davis, A. Merkel, A. Dobin, T. Lassmann et al., Landscape of transcription in human cells, Nature, vol.489, pp.101-108, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01216755

S. R. Eddy, The ENCODE project: missteps overshadowing a success, Curr.Biol, vol.23, pp.259-261, 2013.

K. C. Wang and H. Y. Chang, Molecular mechanisms of long noncoding RNAs, Mol Cell, vol.43, pp.904-914, 2011.

T. R. Cech and J. A. Steitz, The noncoding RNA revolutiontrashing old rules to forge new ones, Cell, vol.157, pp.77-94, 2014.

T. R. Mercer, M. E. Dinger, and J. S. Mattick, Long non-coding RNAs: insights into functions, Nat Rev Genet, vol.10, pp.155-159, 2009.

J. T. Lee, Epigenetic regulation by long noncoding RNAs, Science, vol.338, pp.1435-1439, 2012.

V. Tripathi, J. D. Ellis, Z. Shen, D. Y. Song, Q. Pan et al., The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation, Mol Cell, vol.39, pp.925-938, 2010.

G. A. De, J. Krell, V. Harding, J. Stebbing, and L. Castellano, Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN, Mol Cell Biol, vol.33, pp.3976-3982, 2013.

Y. Tay, J. Rinn, and P. Pp, The multilayered complexity of ceRNA crosstalk and competition, Nature, vol.505, pp.344-352, 2014.

A. Rodriguez, S. Griffiths-jones, J. L. Ashurst, and B. A. , Identification of mammalian microRNA host genes and transcription units, Genome Res, vol.14, pp.1902-1910, 2004.

W. P. Tsang, E. K. Ng, S. S. Ng, J. H. Yu, J. Sung et al., Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer, Carcinogenesis, vol.31, pp.350-358, 2010.

J. R. Prensner and A. M. Chinnaiyan, The emergence of lncRNAs in cancer biology, Cancer Discov, vol.1, pp.391-407, 2011.

S. W. Cheetham, F. Gruhl, J. S. Mattick, and D. Me, Long noncoding RNAs and the genetics of cancer, Br J Cancer, vol.108, pp.2419-2425, 2013.

X. Hu, Y. Feng, D. Zhang, S. D. Zhao, Z. Hu et al., A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer, Cancer Cell, vol.26, pp.344-357, 2014.

J. Zhao, T. K. Ohsumi, J. T. Kung, Y. Ogawa, D. J. Grau et al.,

, Genome-wide identification of polycomb-associated RNAs by RIP-seq, Mol Cell, vol.40, pp.939-953, 2010.

Y. W. Yang, R. A. Flynn, Y. Chen, K. Qu, B. Wan et al., Essential role of lncRNA binding for WDR5 maintenance of active chromatin and embryonic stem cell pluripotency, Elife, vol.3, p.2046, 2014.

J. T. Kung, D. Colognori, and L. Jt, Long noncoding RNAs: past, present, and future, Genetics, vol.193, pp.651-669, 2013.

M. C. Tsai, O. Manor, Y. Wan, N. Mosammaparast, . Wangjk et al., Long noncoding RNA as modular scaffold of histone modification complexes, Science, vol.329, pp.689-693, 2010.

K. Sarma, C. Cifuentes-rojas, A. Ergun, R. A. Del, Y. Jeon et al., ATRX directs binding of PRC2 to Xist RNA and Polycomb targets, Cell, vol.159, pp.869-883, 2014.

S. Geisler and J. Coller, RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts, Nat. Rev.Mol.Cell Biol, vol.14, pp.699-712, 2013.

T. Mondal, S. Subhash, R. Vaid, S. Enroth, S. Uday et al.,

A. Gyllensten, U. Jones, and S. J. , MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triplex structures, Nat.Commun, vol.6, p.7743, 2015.

J. L. Rinn, M. Kertesz, J. K. Wang, S. L. Squazzo, X. Xu et al., Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs, Cell, vol.129, pp.1311-1323, 2007.

T. C. Roberts, K. V. Morris, and M. S. Weinberg, Perspectives on the mechanism of transcriptional regulation by long noncoding RNAs, Epigenetics, vol.9, pp.13-20, 2014.

A. Gabory, H. Jammes, and D. L. , The H19 locus: role of an imprinted non-coding RNA in growth and development, Bioessays, vol.32, pp.473-480, 2010.

A. Gabory, M. A. Ripoche, D. A. Le, F. Watrin, A. Ziyyat et al., H19 acts as a trans regulator of the imprinted gene network controlling growth in mice, Development, vol.136, pp.3413-3421, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02194081

F. Aguilo, M. M. Zhou, and W. Mj, Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression, Cancer Res, vol.71, pp.5365-5369, 2011.

L. Poliseno, L. Salmena, J. Zhang, B. Carver, W. J. Haveman et al., A coding-independent function of gene and pseudogene mRNAs regulates tumour biology, Nature, vol.465, pp.1033-1038, 2010.

J. U. Guo, V. Agarwal, H. Guo, and B. Dp, Expanded identification and characterization of mammalian circular RNAs, Genome Biol, vol.15, p.409, 2014.

J. A. Broderick and P. D. Zamore, Competitive endogenous RNAs cannot alter microRNA function in vivo, Mol Cell, vol.54, pp.711-713, 2014.

Y. Gao, H. Meng, S. Liu, J. Hu, Y. Zhang et al., LncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b, Hum Mol Genet, vol.24, pp.841-852, 2015.

A. N. Kallen, X. B. Zhou, J. Xu, C. Qiao, J. Ma et al., The imprinted H19 lncRNA antagonizes let-7 microRNAs, Mol Cell, vol.52, pp.101-112, 2013.

A. Wilczynska and M. Bushell, The complexity of miRNAmediated repression, Cell Death.Differ, vol.22, pp.22-33, 2015.

D. P. Bartel, MicroRNAs: target recognition and regulatory functions, Cell, vol.136, pp.215-233, 2009.

M. Ha and K. Vn, Regulation of microRNA biogenesis, Nat.Rev.Mol.Cell Biol, vol.15, pp.509-524, 2014.

I. Godnic, M. Zorc, S. D. Jevsinek, G. A. Calin, S. Horvat et al., Genome-wide and species-wide in silico screening for intragenic MicroRNAs in human, mouse and chicken, PLoS.One, vol.8, p.65165, 2013.

Z. Du, T. Fei, R. G. Verhaak, Z. Su, Y. Zhang et al., Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer, Nat Struct Mol Biol, vol.20, pp.908-913, 2013.

, Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma, Nature, vol.474, pp.609-615, 2011.

R. Akrami, A. Jacobsen, J. Hoell, N. Schultz, C. Sander et al., Comprehensive analysis of long non-coding RNAs in ovarian cancer reveals global patterns and targeted DNA amplification, PLoS One, vol.8, p.80306, 2013.

C. M. Clemson, J. N. Hutchinson, S. A. Sara, A. W. Ensminger, A. H. Fox et al., An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles, Mol Cell, vol.33, pp.717-726, 2009.

Y. S. Kim, J. D. Hwan, S. Bae, D. H. Bae, and S. Wa, Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma, BMC Cancer, vol.10, p.576, 2010.

F. Wang, J. Zhou, X. Xie, J. Hu, L. Chen et al., Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells, Neoplasma, vol.62, pp.432-438, 2015.

K. Odunsi, P. Mhawech-fauceglia, C. Andrews, A. Beck, O. Amuwo et al., Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro, PLoS.One, vol.7, p.51030, 2012.

D. S. Perez, T. R. Hoage, J. R. Pritchett, A. L. Ducharme-smith, M. L. Halling et al., Long, abundantly expressed non-coding transcripts are altered in cancer, www.impactjournals.com/oncotarget, vol.17, pp.1180-1189, 2008.

X. Han, F. Yang, H. Cao, and Z. Liang, Malat1 regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis, FASEB J, vol.29, pp.3054-3064, 2015.

F. Xu, F. Li, W. Zhang, and P. Jia, Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression, Tumour.Biol, vol.36, pp.9553-9561, 2015.

C. Denoyelle, B. Lambert, M. Meryet-figuiere, N. Vigneron, E. Brotin et al., miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation, Cell Death.Dis, vol.5, p.1445, 2014.

B. Gloss, K. Moran-jones, V. Lin, M. Gonzalez, J. Scurry et al., ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer, Mol Cancer, vol.13, p.3, 2014.

Z. Cheng, J. Guo, L. Chen, N. Luo, W. Yang et al., A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer, Oncotarget, vol.6, pp.25381-25389, 2015.

L. B. Rangel, C. A. Sherman-baust, R. P. Wernyj, D. R. Schwartz, K. R. Cho et al., Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression, Oncogene, vol.22, pp.7225-7232, 2003.

J. M. Silva, N. J. Boczek, M. W. Berres, X. Ma, and S. Di, LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation, RNA Biol, vol.8, pp.496-505, 2011.

M. D. Xu, P. Qi, W. W. Weng, X. H. Shen, S. J. Ni et al., Long noncoding RNA LSINCT5 predicts negative prognosis and exhibits oncogenic activity in gastric cancer, Medicine (Baltimore), vol.93, p.303, 2014.

Y. Guan, W. L. Kuo, J. L. Stilwell, H. Takano, A. V. Lapuk et al., Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer, Clin Cancer Res, vol.13, pp.5745-5755, 2007.

Y. Y. Tseng, B. S. Moriarity, W. Gong, R. Akiyama, A. Tiwari et al., PVT1 dependence in cancer with MYC copy-number increase, Nature, vol.512, pp.82-86, 2014.

K. Huppi, N. Volfovsky, T. Runfola, T. L. Jones, M. Mackiewicz et al., The identification of microRNAs in a genomically unstable region of human chromosome 8q24, Mol Cancer Res, vol.6, pp.212-221, 2008.

E. Liu, Z. Liu, and Y. Zhou, Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1, Int.J Clin Exp.Pathol, vol.8, pp.3803-3810, 2015.

D. C. Corney, A. Flesken-nikitin, J. Choi, and A. Y. Nikitin, Role of p53 and Rb in ovarian cancer, Adv.Exp.Med.Biol, vol.622, pp.99-117, 2008.

Y. Yao, J. Ma, Y. Xue, P. Wang, Z. Li et al., Knockdown of long noncoding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152, Cancer Lett, vol.359, pp.75-86, 2015.

E. Yildirim, J. E. Kirby, D. E. Brown, F. E. Mercier, R. I. Sadreyev et al., Xist RNA is a potent suppressor of hematologic cancer in mice, Cell, vol.152, pp.727-742, 2013.

T. Kawakami, C. Zhang, T. Taniguchi, C. J. Kim, Y. Okada et al., Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells, Oncogene, vol.23, pp.6163-6169, 2004.

K. C. Huang, P. H. Rao, C. C. Lau, E. Heard, S. K. Ng et al., Relationship of XIST expression and responses of ovarian cancer to chemotherapy, Mol Cancer Ther, vol.1, pp.769-776, 2002.

M. C. Tsai, O. Manor, Y. Wan, N. Mosammaparast, J. K. Wang et al., Long noncoding RNA as modular scaffold of histone modification complexes, Science, vol.329, pp.689-693, 2010.

R. A. Gupta, N. Shah, K. C. Wang, J. Kim, H. M. Horlings et al., Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis, Nature, vol.464, pp.1071-1076, 2010.

T. Gutschner and S. Diederichs, The hallmarks of cancer: a long non-coding RNA point of view, RNA Biol, vol.9, pp.703-719, 2012.

J. J. Qiu, Y. Wang, J. X. Ding, H. Y. Jin, G. Yang et al., The long non-coding RNA HOTAIR promotes the proliferation of serous ovarian cancer cells through the regulation of cell cycle arrest and apoptosis, Exp.Cell Res, vol.333, pp.238-248, 2015.

A. E. Teschendorff, S. H. Lee, A. Jones, H. Fiegl, M. Kalwa et al., HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer, Genome Med, vol.7, p.108, 2015.

D. J. Marsh, J. S. Shah, and C. Aj, Histones and their modifications in ovarian cancer -drivers of disease and therapeutic targets, Front Oncol, vol.4, p.144, 2014.

J. Li, S. Yang, N. Su, Y. Wang, J. Yu et al., Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/beta-catenin pathway in human ovarian cancer, Tumour.Biol, 2015.

J. J. Qiu, Y. Y. Lin, L. C. Ye, J. X. Ding, W. W. Feng et al., Overexpression of long noncoding RNA HOTAIR predicts poor patient prognosis and www.impactjournals.com/oncotarget promotes tumor metastasis in epithelial ovarian cancer, Gynecol Oncol, vol.134, pp.121-128, 2014.

C. Y. Xing, X. Q. Hu, F. Y. Xie, Z. J. Yu, H. Y. Li et al., Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia, FEBS Lett, vol.589, pp.1981-1987, 2015.

H. Nakano, Y. Yamada, T. Miyazawa, and Y. T. , Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells, Int.J Oncol, vol.42, pp.1875-1882, 2013.

W. Cheng, J. Liu, H. Yoshida, D. Rosen, and H. Naora, Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract, Nat.Med, vol.11, pp.531-537, 2005.

E. J. Richards, J. Permuth-wey, Y. Li, Y. A. Chen, D. Coppola et al., A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer, Oncotarget, vol.6, pp.34745-57, 2015.

A. Congrains, K. Kamide, M. Ohishi, and H. Rakugi, ANRIL: Molecular Mechanisms and Implications in Human Health, Int.J Mol.Sci, vol.14, pp.1278-1292, 2013.

E. Pasmant, A. Sabbagh, M. Vidaud, B. I. Anril, and . Long, noncoding RNA, is an unexpected major hotspot in GWAS, FASEB J, vol.25, pp.444-448, 2011.

J. Gil and G. Peters, Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all, Nat.Rev. Mol.Cell Biol, vol.7, pp.667-677, 2006.

A. Hendrayani, S. F. Tulbah, A. Al-tweigeri, T. Shehata, A. I. et al., p16INK4A represses breast stromal fibroblasts migration/invasion and their VEGF-A-dependent promotion of angiogenesis through Akt inhibition, Neoplasia, vol.14, pp.1269-1277, 2012.

J. J. Qiu, Y. Y. Lin, J. X. Ding, W. W. Feng, H. Y. Jin et al., Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer, Int.J Oncol, vol.46, pp.2497-2505, 2015.

C. Balch, F. Fang, D. E. Matei, T. H. Huang, and N. Kp, Minireview: epigenetic changes in ovarian cancer, Endocrinology, vol.150, pp.4003-4011, 2009.

Y. Zhou, X. Zhang, and A. Klibanski, MEG3 noncoding RNA: a tumor suppressor, J Mol Endocrinol, vol.48, pp.45-53, 2012.

M. Sun, R. Xia, J. F. Xu, T. Liu, Z. De et al., Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer, Tumour Biol, vol.35, pp.1065-1073, 2014.

D. D. Yin, Z. J. Liu, E. Zhang, R. Kong, Z. H. Zhang et al., Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer, Tumour Biol, vol.36, pp.4851-4860, 2015.

Y. Zhou, Y. Zhong, Y. Wang, X. Zhang, D. L. Batista et al., Activation of p53 by MEG3 non-coding RNA, J Biol Chem, vol.282, pp.24731-24742, 2007.

X. Sheng, J. Li, L. Yang, Z. Chen, Q. Zhao et al., Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer, Oncol Rep, vol.32, pp.277-285, 2014.

J. Yan, X. Guo, J. Xia, T. Shan, C. Gu et al., MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1, Med Oncol, vol.31, p.879, 2014.

Y. Gu, M. Zhang, F. Peng, L. Fang, Y. Zhang et al., The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2, Oncotarget, vol.6, pp.2397-2406, 2015.

L. F. Jia, S. B. Wei, Y. H. Gan, Y. Guo, K. Gong et al., Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma, Int J Cancer, vol.135, pp.2282-2293, 2014.

W. Shen, M. Song, J. Liu, G. Qiu, T. Li et al., MiR-26a promotes ovarian cancer proliferation and tumorigenesis, PLoS.One, vol.9, p.86871, 2014.

W. Peng, S. Si, Q. Zhang, C. Li, F. Zhao et al., Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression, J Exp.Clin Cancer Res, vol.34, p.79, 2015.

A. Parikh, C. Lee, P. Joseph, S. Marchini, A. Baccarini et al., microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition, Nat. Commun, vol.5, p.2977, 2014.

M. Luo, Z. Li, W. Wang, Y. Zeng, Z. Liu et al., Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression, Cancer Lett, vol.333, pp.213-221, 2013.

A. Mizrahi, A. Czerniak, T. Levy, S. Amiur, J. Gallula et al., Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences, J Transl Med, vol.7, p.69, 2009.

V. Tanos, D. Prus, S. Ayesh, D. Weinstein, M. L. Tykocinski et al., Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer, Eur J Obstet Gynecol Reprod Biol, vol.85, pp.7-11, 1999.

T. Yoshimizu, A. Miroglio, M. A. Ripoche, A. Gabory, M. Vernucci et al., The H19 locus acts in vivo as a tumor suppressor, Proc Natl Acad Sci, vol.105, pp.12417-12422, 2008.

L. Yan, J. Zhou, Y. Gao, S. Ghazal, L. Lu et al., Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation, Oncogene, vol.34, pp.3076-84, 2015.

J. M. Hernandez, A. Elahi, C. W. Clark, J. Wang, L. A. Humphries et al., miR-675 mediates downregulation of Twist1 and Rb in AFP-secreting hepatocellular carcinoma, Ann Surg Oncol, vol.20, issue.3, pp.625-635, 2013.

Y. Shi, Y. Wang, W. Luan, P. Wang, T. Tao et al., Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675, PLoS One, vol.9, p.86295, 2014.

I. J. Matouk, E. Raveh, R. Abu-lail, S. Mezan, M. Gilon et al., Oncofetal H19 RNA promotes tumor metastasis, Biochim Biophys Acta, vol.1843, pp.1414-1426, 2014.

A. Honig, C. Weidler, S. Hausler, M. Krockenberger, S. Buchholz et al., Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer, Anticancer Res, vol.30, pp.1559-1564, 2010.

R. Bhattacharya, M. Nicoloso, R. Arvizo, E. Wang, A. Cortez et al., MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer, Cancer Res, vol.69, pp.9090-9095, 2009.

F. Zhang, L. Sui, and T. Xin, Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues, Exp Oncol, vol.30, pp.70-74, 2008.

E. Wang, S. Bhattacharyya, A. Szabolcs, C. Rodriguez-aguayo, N. B. Jennings et al., Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer, PLoS One, vol.6, 2011.

Z. Y. Rao, M. Y. Cai, G. F. Yang, L. R. He, S. J. Mai et al., EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients, Carcinogenesis, vol.31, pp.1576-1583, 2010.

A. Semaan, A. M. Qazi, S. Seward, S. Chamala, C. S. Bryant et al.,

, MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)/cip(1)), Pharm Res, vol.28, pp.3079-3090, 2011.

S. Hu, L. Yu, Z. Li, Y. Shen, J. Wang et al., Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo, Cancer Biol Ther, vol.10, pp.788-795, 2010.

S. Seward, A. Semaan, A. M. Qazi, O. V. Gruzdyn, S. Chamala et al., EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53, Cancer Lett, vol.336, pp.53-60, 2013.

E. J. Nam, H. Yoon, S. W. Kim, H. Kim, Y. T. Kim et al., MicroRNA expression profiles in serous ovarian carcinoma, Clin Cancer Res, vol.14, pp.2690-2695, 2008.

S. Shell, S. M. Park, A. R. Radjabi, R. Schickel, E. O. Kistner et al., Let-7 expression defines two differentiation stages of cancer, Proc Natl Acad Sci, vol.104, pp.11400-11405, 2007.

N. Dahiya, C. A. Sherman-baust, T. L. Wang, B. Davidson, I. Shih et al., MicroRNA expression and identification of putative miRNA targets in ovarian cancer, PLoS One, vol.3, p.2436, 2008.

N. Yang, S. Kaur, S. Volinia, J. Greshock, H. Lassus et al., MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer, Cancer Res, vol.68, pp.10307-10314, 2008.

L. Lu, D. Katsaros, I. A. De-la-longrais, O. Sochirca, and Y. H. , Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis, Cancer Res, vol.67, pp.10117-10122, 2007.

J. Cai, C. Yang, Q. Yang, H. Ding, J. Jia et al., Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin, Oncogenesis, vol.2, p.75, 2013.

D. Kong, E. Heath, W. Chen, M. L. Cher, I. Powell et al., Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM, PLoS One, vol.7, p.33729, 2012.

Z. Tang, G. S. Ow, J. P. Thiery, A. V. Ivshina, and K. Va, Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma, Int J Cancer, vol.134, pp.306-318, 2014.

G. H. Leyten, D. Hessels, S. A. Jannink, F. P. Smit, J. H. De et al., Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer, Eur Urol, vol.65, pp.534-542, 2014.

R. Kumarswamy, C. Bauters, I. Volkmann, F. Maury, J. Fetisch et al., Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure, Circ.Res, vol.114, pp.1569-1575, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02267443

H. Li and R. Zhang, Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target, Front Oncol, vol.3, p.47, 2013.

M. T. Mccabe, H. M. Ott, G. Ganji, S. Korenchuk, C. Thompson et al., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations, Nature, vol.492, pp.108-112, 2012.

A. Mizrahi, A. Hochberg, S. Amiur, J. Gallula, I. Matouk et al., Targeting diphtheria toxin and TNF alpha expression in ovarian tumors using the H19 regulatory sequences, Int J Clin Exp Med, vol.3, pp.270-282, 2010.

A. Mizrahi, A. Czerniak, P. Ohana, S. Amiur, J. Gallula et al., Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report, J Med Case Rep, vol.4, p.228, 2010.